SI1673106T1 - Optimiziran izraz hpv 45 l1 v kvasovki - Google Patents

Optimiziran izraz hpv 45 l1 v kvasovki

Info

Publication number
SI1673106T1
SI1673106T1 SI200431180T SI200431180T SI1673106T1 SI 1673106 T1 SI1673106 T1 SI 1673106T1 SI 200431180 T SI200431180 T SI 200431180T SI 200431180 T SI200431180 T SI 200431180T SI 1673106 T1 SI1673106 T1 SI 1673106T1
Authority
SI
Slovenia
Prior art keywords
hpv
yeast
optimized expression
optimized
expression
Prior art date
Application number
SI200431180T
Other languages
English (en)
Slovenian (sl)
Inventor
Janine T Bryan
Michelle K Brownlow
Loren D Schultz
Kathrin U Jansen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SI1673106T1 publication Critical patent/SI1673106T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SI200431180T 2003-09-29 2004-09-24 Optimiziran izraz hpv 45 l1 v kvasovki SI1673106T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast
EP04788982A EP1673106B1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (1)

Publication Number Publication Date
SI1673106T1 true SI1673106T1 (sl) 2009-12-31

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431180T SI1673106T1 (sl) 2003-09-29 2004-09-24 Optimiziran izraz hpv 45 l1 v kvasovki

Country Status (33)

Country Link
US (2) US7250170B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1673106B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP5451960B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101165278B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1859923B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR045804A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE435029T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2004277934B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2015C072I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0414845B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2539168C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110525T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602004021828D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1673106T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2327530T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR15C0083I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1500063I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL174458A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2694B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (2) LTC1673106I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92902I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA06003457A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY140664A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300776I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO339932B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ545834A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1673106T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1673106E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2360001C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1673106T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI350853B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2005032586A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200601961B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
BRPI0509079B8 (pt) 2004-03-24 2021-07-06 Merck & Co Inc molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)
US8101342B2 (en) * 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
AU2008226974B2 (en) * 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
WO2009076824A1 (zh) * 2007-11-23 2009-06-25 Shanghai Zerun Biotechnology Co., Ltd. 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
CN104288763B (zh) 2009-06-19 2018-03-06 艾金株式会社 宫颈癌疫苗
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
AU2012270418B2 (en) * 2011-06-15 2015-08-13 Posvax Co., Ltd Method for enhancing the production yield of human papillomavirus L1 protein
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CA2958222A1 (en) * 2014-09-11 2016-03-17 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
KR20240046247A (ko) 2021-08-19 2024-04-08 머크 샤프 앤드 돔 엘엘씨 열안정성 지질 나노입자 및 그의 사용 방법
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ336696A3 (en) * 1994-05-16 1997-07-16 Merck & Co Inc Isolated and purified proteins of papillomavirus and process for preparing thereof
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DE69836206T2 (de) 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
JP3366339B2 (ja) * 1997-05-27 2003-01-14 ハニル シンセティック ファイバー カンパニー リミテッド 高効率発現ベクターを用いてサッカロミセスセレビジエから再組合蛋白質を製造する方法
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
AU753391B2 (en) * 1998-08-14 2002-10-17 Merck Sharp & Dohme Corp. Protein delivery system using human papillomavirus virus-like particles
BR9913026A (pt) * 1998-08-14 2001-09-25 Merck & Co Inc Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
AU763853B2 (en) * 1998-12-23 2003-07-31 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
ES2277605T3 (es) 2000-07-21 2007-07-16 Glaxo Group Limited Secuencias de papilomavirus de codones optimizados.
AU2003213060A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
RU2356943C2 (ru) 2003-03-24 2009-05-27 Мерк Энд Ко., Инк. Молекула нуклеиновой кислоты, кодирующая hpv31 l1, экспрессирующий вектор, клетка-хозяин, вирусоподобная частица и способ ее получения, вакцина, фармацевтическая композиция и способы с их использованием

Also Published As

Publication number Publication date
MY140664A (en) 2010-01-15
US20080138361A1 (en) 2008-06-12
JP2014221052A (ja) 2014-11-27
CY2015050I1 (el) 2016-06-22
KR20070029628A (ko) 2007-03-14
HUS1500063I1 (hu) 2016-02-29
FR15C0083I2 (fr) 2016-11-25
PT1673106E (pt) 2009-09-22
MXPA06003457A (es) 2006-06-05
JP2011152137A (ja) 2011-08-11
EP1673106A1 (en) 2006-06-28
BE2015C072I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-12-14
CY2015050I2 (el) 2016-06-22
ES2327530T3 (es) 2009-10-30
LTPA2015049I1 (lt) 2016-01-11
CN1859923B (zh) 2012-09-05
DK1673106T3 (da) 2009-11-09
EP1673106B1 (en) 2009-07-01
CY1110525T1 (el) 2015-04-29
AR077396A2 (es) 2011-08-24
JP5451960B2 (ja) 2014-03-26
NO2022051I1 (no) 2022-11-30
NL300776I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-12-29
JP2016136947A (ja) 2016-08-04
NL300776I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-12-29
CA2539168C (en) 2011-05-31
BRPI0414845A (pt) 2006-11-21
NO339932B1 (no) 2017-02-20
IL174458A0 (en) 2006-08-01
IS2694B (is) 2010-11-15
US7250170B2 (en) 2007-07-31
AR045804A1 (es) 2005-11-16
CN1859923A (zh) 2006-11-08
NZ545834A (en) 2009-02-28
IL174458A (en) 2014-06-30
NO2017012I1 (no) 2017-04-05
ZA200601961B (en) 2007-05-30
KR101165278B1 (ko) 2012-07-23
IS8362A (is) 2006-03-20
AU2004277934A1 (en) 2005-04-14
RU2360001C2 (ru) 2009-06-27
DE602004021828D1 (de) 2009-08-13
PL1673106T3 (pl) 2009-12-31
LU92902I2 (fr) 2016-03-08
NO20061876L (no) 2006-04-28
ATE435029T1 (de) 2009-07-15
FR15C0083I1 (fr) 2016-08-01
BRPI0414845B8 (pt) 2021-06-15
US7482015B2 (en) 2009-01-27
US20060240040A1 (en) 2006-10-26
CA2539168A1 (en) 2005-04-14
TW200521233A (en) 2005-07-01
WO2005032586A1 (en) 2005-04-14
JP2007507207A (ja) 2007-03-29
AU2004277934B2 (en) 2009-09-17
TWI350853B (en) 2011-10-21
RU2006114701A (ru) 2007-11-10
LTC1673106I2 (lt) 2017-05-10
BRPI0414845B1 (pt) 2020-10-13

Similar Documents

Publication Publication Date Title
HUS1500064I1 (hu) HPV58 L1 optimalizált expressziója élesztõben
HUS1500063I1 (hu) HPV 45 L1 optimalizált expresszáltatása élesztõben
HUS1500062I1 (hu) HPV 52 L1 optimalizált expresszáltatása élesztõben
AU2002951692A0 (en) Improvements in or relating to vaccines
EP1654374A4 (en) PROCESS AND FERMENTATION COMPOSITIONS
AU2003243531A1 (en) Fermentation methods and compositions
PL375355A1 (en) Novel lipases and uses thereof
AU2003219093A1 (en) Anti-hpv-16 e7 antibodies and their use
GB2409265B (en) Improvements In and Relating to Stoves
AU2003224732A1 (en) Method of using anti-apoptotic factors in gene expression
AU2003275946A1 (en) Gene expression in biological conditions
GB0311292D0 (en) Improvements in and relating to the movement of metal
GB0214524D0 (en) Improvements in or relating to regulation of gene expression
GB0317335D0 (en) Improvements in and relating to interpretation
AU2003283530A1 (en) Improvements in and relating to gas cleaning devices
AU2002237468A1 (en) Well with tank and method to carry out thereof
AU2003244824A1 (en) Improvements in and relating to pumps
AU2003904127A0 (en) Improvements in and relating to joints
GB0319436D0 (en) Improvements in enzymes